secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001193125-22-280159
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INOVIO Q3 net loss narrows to $0.15/sh; cash runway into Q1 2025
----------------------------------------------------------------

- Q3 2022 revenue of $9.2M vs $292K in Q3 2021, driven by DoD contract.
- Net loss $37.8M ($0.15/sh) vs $60.2M ($0.29/sh) prior year; OpEx down to $44.9M.
- Cash and investments $281.9M; guidance extended to early 2025 with ~$45M Q4 cash burn.
- Discontinued internal INO-4800 heterologous COVID-19 booster; redeploying savings to other programs.
- Positive interim INO-3107 data: median 3 fewer RRP surgeries; 29% needed no intervention in 52 weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312522280159/0001193125-22-280159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312522280159/d280542d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-280159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer